Nurse practitioner commentary ties GLP-1 microdosing to cost barriers and weight bias

A commentary published May 26, 2026, in the Journal of the American Association of Nurse Practitioners says affordability barriers continue to drive patients toward unsupervised "microdosing" of GLP-1 medications and toward unapproved "research-grade" peptides bought online, even after federal pricing agreements aimed at lowering the cost of these drugs ^[1][2].

The piece, written by nurse practitioner Nicole Trainer, appears in the journal's Commentaries & Columns section and was released ahead of print ^[2]. It is framed as a briefing for nurse practitioners on what to do as the rules for compounded versions of semaglutide and tirzepatide have tightened. According to the commentary, the US Food and Drug Administration's resolution of shortages of both drugs has "fundamentally altered the regulatory landscape" for compounded obesity medications, and the regulatory window on mass compounding is closing ^[1][2].

What the commentary says drives microdosing

"Microdosing" here means deliberately taking a dose below the therapeutic level — less than what would be expected to produce the drug's intended effect — rather than a formally studied regimen ^[1][2]. The commentary identifies two reasons patients do it: gastrointestinal tolerability and what it calls "vanity weight" goals ^[1][2].

It also lists the harms it associates with the practice: side effects and dosing errors, safety risks from manipulating injection pens, from compounded vials and from sharing medication, and legal pitfalls around compounded "copies" of brand-name products ^[1][2]. The authors state that legitimate compounding still has a narrow role, specifically for patients with a documented allergy ^[1][2].

Separately, the commentary examines provider weight bias as a driver that sends patients to unregulated alternatives instead of raising the subject with a clinician, and it offers strategies for nurse practitioners to reduce stigma during visits ^[1][2].

Why it matters for patients

Cost is the mechanism the commentary points to: federal pricing agreements lowered some GLP-1 prices, but the authors say affordability barriers persist and are fueling what they describe as patient desperation ^[1][2]. People who cannot afford a prescribed dose may look for a cheaper route, including products sold by online sources and unregulated providers such as medical spas ^[1][2].

The practical risks named in the commentary are ones patients would experience directly. Sharing medication and manipulating pens can lead to dosing errors, and compounded vials and illicit peptides fall outside the FDA's approval process for safety and purity ^[1][2]. Because the shortage that once allowed broad compounding has been resolved, compounded "copies" are on narrower legal footing than during the shortage period ^[1][2].

The stigma point cuts a different way. If patients expect to be judged about their weight, the commentary suggests they may skip the conversation with a prescriber entirely and go around the health system — which means no monitoring and no one tracking side effects ^[1][2].

What is not yet known

The commentary's publicly available abstract does not give prevalence numbers for microdosing, does not list the specific doses involved, and does not quantify how often the side effects or dosing errors occurred ^[1][2]. It reports no new clinical trial results and announces no regulatory or company action ^[1][2]. The full text is available only to subscribers of the journal ^[2]. No follow-up study or policy change has been announced ^[2].